Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases

脑特异性酶胆固醇 24-羟化酶 (Cyp46A1) 作为人类朊病毒疾病的新型治疗靶点

• 批准号: 440680
• 负责人: Ali Tahir
• 金额: $ 9.83万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=440680&lang=en
• 关键词: Brain Cholesterol Metabolism; Cellular Models Of Prion Diseases; Cholesterol 24-Hydroxylase (Cyp46a1); Cyp46a1 Activator (Efavirenz); Fda-Approved Repurposed Drug (Efavirenz); Human Prion Diseases; Mouse Models Of Human Prion Diseases; Neurodegenerative D

Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease which has b

朊病毒疾病是影响人类和动物的传染性和致命的神经退行性疾病。克雅氏病是人类最常见的朊病毒疾病。动物朊病毒疾病包括绵羊/山羊痒病和疯牛病